Furthermore, the resistance to anti-VEGF therapy is due to the upregulation of alternative pro-angiogenic signals in tumor-associated ECs, such as genes involved in posttranscriptional collagen modification that could represent possible alternative angiogenic candidates (14). This evidence concerns the gene VEGFA and neoplasm.